More than one in two Irish parents say their child missed schools days in the past year due to flu or flu-like symptoms with ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

But the picture is mixed. A phase I trial of a nasal formulation of the Oxford AstraZeneca vaccine showed little to no induction of mucosal immunity and weaker systemic antibody responses compared ...

The Irish Patients Association is calling on parents and guardians of children to join together with them in ‘Flunion’ in the ...

Participants in the trial were symptomatic despite treatment with standard of care, intranasal corticosteroids ... Live Attenuated Vaccines The concomitant use of TEZSPIRE and live attenuated ...

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...

Six months after Amgen and AstraZeneca reported promising results ... and clinically meaningful reduction in polyp size and nasal congestion in patients with severe chronic rhinosinusitis with ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).